Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
Aminobutyrates
/ therapeutic use
Angiotensin Receptor Antagonists
/ therapeutic use
Biphenyl Compounds
/ therapeutic use
Black People
Drug Combinations
Female
Heart Failure
/ drug therapy
Humans
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Quality of Life
Retrospective Studies
Stroke Volume
/ drug effects
Valsartan
/ therapeutic use
White People
Journal
Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
12
10
2021
medline:
16
2
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
The aim of this study was to determine the degree of short-term improvement in left ventricular ejection fraction (LVEF), haemodynamics, NT-proBNP and quality of life following initiation of sacubitril/valsartan in black patients when compared with white patients. This was a retrospective, observational, single-centre, hypothesis-generating study of patients with symptomatic heart failure and reduced ejection fraction (HFrEF) treated with guideline recommended therapy, who were transitioned from an ACE inhibitor (ACE-I) or angiotensin receptor blocker (ARB) to sacubitril/valsartan. Our analysis included 83 patients (mean age 57 years) with echocardiography performed before and after transition from ACE-I/ARB to sacubitril/valsartan, after excluding patients with concomitant Cardiac resynchronization therapy implantation. Overall, sacubitril/valsartan was associated with LVEF improvement from 28.8% ± 0.7 to 32.0% ± 1.1% (P = 0.0002), but no reverse remodelling was observed. The association with LVEF improvement was only observed in white patients (n = 46, P = 0.0006), but not in black patients (n = 37, P = 0.1728), and appeared to be associated with reduced blood pressure (baseline vs. 2-week blood pressure 116.5 ± 13.9 vs. 109.4 ± 14.3 mmHg, respectively, in white patients, P = 0.0449). Fifteen patients (18.1%) became ineligible for primary prevention Implantable cardioverter defibrillator implantation. Sacubitril/valsartan was associated with improved LVEF, NT-proBNP concentrations and quality of life in patients with symptomatic HFrEF on guideline recommended therapy. However, in our cohort, improvement of LVEF and quality of life might be attenuated in black patients, which warrants further investigation.
Identifiants
pubmed: 34632983
doi: 10.2459/JCM.0000000000001268
pii: 01244665-202201000-00005
doi:
Substances chimiques
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Biphenyl Compounds
0
Drug Combinations
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Valsartan
80M03YXJ7I
sacubitril and valsartan sodium hydrate drug combination
WB8FT61183
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-41Informations de copyright
Copyright © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
Références
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.
Januzzi JL Jr, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019; 322:1085–1095.
Almufleh A, Marbach J, Chih S, et al. Ejection fraction improvement and reverse remodeling achieved with sacubitril/valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis 2017; 7:108–113.
Martens P, Belien H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther 2018; 36:e12435.
Benjamin EJ, Virani SS, Callaway CW, et al. Heart Disease and Stroke Statistics-2018 Update: a report from the American Heart Association. Circulation 2018; 137:e67–e492.
Giblin EM, Adams KF Jr, Hill L, et al. Comparison of hydralazine/nitrate and angiotensin receptor neprilysin inhibitor use among black versus nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). Am J Cardiol 2019; 124:1900–1906.
Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM. Comparative effectiveness of Sacubitril-Valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction. JACC Heart Fail 2020; 8:43–54.
Berardi C, Braunwald E, Morrow DA, et al. Angiotensin-neprilysin inhibition in black Americans: data from the PIONEER-HF trial. JACC Heart Fail 2020; 8:859–866.
Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 2016; 133:1115–1124.
Burke RM, Lighthouse JK, Mickelsen DM, Small EM. Sacubitril/Valsartan decreases cardiac fibrosis in left ventricle pressure overload by restoring PKG signaling in cardiac fibroblasts. Circ Heart Fail 2019; 12:e005565.
Ibrahim NE, Pina IL, Camacho A, et al. Racial and ethnic differences in biomarkers, health status, and cardiac remodeling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. Circ Heart Fail 2020; 13:e007829.
Gupta DK, Claggett B, Wells Q, et al. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc 2015; 4:e001831 https://doi.org/10.1161/JAHA.115.001831
doi: 10.1161/JAHA.115.001831
Gupta DK, de Lemos JA, Ayers CR, Berry JD, Wang TJ. Racial differences in natriuretic peptide levels: the Dallas Heart Study. JACC Heart Fail 2015; 3:513–519.
Dries DL, Victor RG, Rame JE, et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation 2005; 112:2403–2410.
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019; 380:539–548.
Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. Ann Pharmacother 2018; 52:1143–1151.
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772–776.
Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40:1414–1421.
El-Refai M, Hrobowski T, Peterson EL, et al. Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure. J Cardiovasc Med (Hagerstown) 2015; 16:591–596.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37:2129–2200.
Bosworth HB, Dudley T, Olsen MK, et al. Racial differences in blood pressure control: potential explanatory factors. Am J Med 2006; 119:70e9–15.